Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Active, not recruiting · Phase 2 · NCT05859334
Conditions: Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
At a glance
- Research payments reported, 2025
- $22,400
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- National Cancer Institute (NCI)
- Tested
- Biospecimen Collection (procedure), Erdafitinib (drug), Magnetic Resonance Imaging (procedure), Optical Coherence Tomography (procedure)
- Dates
- Started 2024-01-04; completion 2027-10-23
- Results posted
- Not yet
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.
From ClinicalTrials.gov, last updated 2026-10-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Caris Mpi, Inc. reported $22,400 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Miami $22,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.